Does Mold Only Cause Allergies? What 20 Years of Research Actually Shows

On November 12, 2024, the American Academy of Allergy, Asthma & Immunology published a public article arguing that "toxic mold syndrome" is not supported as an explanation for fatigue, brain fog, mood changes, and other wide-ranging symptoms (AAAAI 2024).

That sounds precise, but the article does two things at once: it criticizes unvalidated urine mycotoxin tests and simplistic poison narratives, then treats that critique as if it settles whether water-damaged buildings can trigger chronic inflammatory illness.

It doesn't.

In 2020, researchers at the City University of New York stripped every mycotoxin from Stachybotrys chartarum mold spores and gave them to mice. No poison. No allergenic proteins. Just the bare physical shell of the mold. The mice developed brain inflammation and lost the ability to form certain memories (Harding et al. 2020).

The spores weren't toxic. The mice weren't allergic. A third immune pathway, one that doesn't appear on any standard allergy test, did the damage. Two follow-up studies have since reproduced the finding (details in the section below).

That result breaks the premise behind "mold only causes allergies." If your doctor, landlord, or insurer has used that claim to explain away your symptoms, here's what 20 years of published research says they're missing.

Where the AAAAI article is too narrow

The AAAAI article gets one important thing right: "mold toxicity" gets used too loosely. Acute poisoning from a high enough dose of a specific mycotoxin is not the same question as chronic inflammatory illness after water-damaged building exposure. Urine mycotoxin tests also have real limitations, and MoldCo does not use or endorse urine mycotoxin testing for mold-related illness.

But those cautions don't prove the allergy-only claim. They answer a narrower question.

• AAAAI frames adverse mold effects around infection, allergic responses, and direct toxic effects. That leaves out innate immune activation, the pathway Harding's controlled mouse model identified when non-toxic spores still produced brain immune activation and memory effects.
• AAAAI criticizes studies that rely on self-reported symptoms or weak exposure measures. Some mold studies do have that problem. But the evidence base also includes controlled animal work, systematic literature reviews, objective biomarker studies, real-world measurements of how much mold actually reaches people indoors, and clinical case definitions (the symptom-plus-biomarker patterns used to identify mold-related illness in patient populations) from McMahon and others.
• AAAAI leans on older IOM (2004) and WHO (2009) conclusions about insufficient evidence for inhaled mycotoxins causing nonspecific symptoms. Both reviews are now more than 15 years old and predate most of the controlled animal work on innate immune activation. That is not the same as proving damp buildings cannot drive inflammatory illness. Even the AAAAI article acknowledges a clear relationship between damp indoor spaces and adverse health effects, while noting that mechanisms remain uncertain.
• AAAAI warns against costly testing methods that have not been proven. That is a fair warning when the target is direct-to-consumer urine mycotoxin testing. It does not apply cleanly to standard blood biomarkers like MMP-9, TGF-beta1, MSH, and C4a, which are ordered through conventional labs and interpreted in clinical context.
• AAAAI's public social framing conflicts with the NIH's own mold page. NIEHS says mold can affect health in different ways depending on mold type, exposure amount, exposure duration, and the person exposed. It explicitly lists cognitive issues and immune effects among associated mold-related health effects (NIEHS). For those effects, NIEHS specifically cites Harding et al. (2020) on the cognitive findings and a 2015 study on cytokine and chemokine responses to environmental mold for the immune effects.

So the real issue is not whether every symptom should be blamed on mold. It shouldn't. The issue is whether a negative allergy test, or skepticism about urine mycotoxin testing, rules out mold-related inflammatory illness.

It does not.

The experiment that changed the question

Harding and colleagues took Stachybotrys chartarum spores and created two preparations: one with intact mycotoxins (the "toxic" version) and one with all mycotoxins extracted (the "non-toxic" version). They administered both intranasally to mice (Harding et al. 2020).

Both groups showed the same result.

Inflammation surged in the hippocampus (the brain's memory center). New neuron growth dropped. The mice lost the ability to distinguish between safe and threatening contexts, a specific type of memory deficit. The researchers proposed innate immune activation as a fourth mechanism of mold-induced illness, alongside allergy, infection, and direct toxicity.

The mice didn't need to be allergic. The spores didn't need to be poisonous. Their innate immune system (the body's first line of defense, separate from the antibody-driven system that allergists test) recognized the mold's physical shell and launched an inflammatory attack on the brain.

An earlier study from the same research group confirmed these findings in 2012 (Harding et al. 2012). An independent German lab replicated the core result in 2021 (Kraft, Buchenauer & Polte 2021). Three labs. Same conclusion.

"Exposed to high levels of toxic mold for months in a rental home. Brain fog, fatigue, sick more often, working memory clobbered. Treatment with MoldCo has been a huge blessing, finally recovering. If not for them mold wouldn't even be on my radar as a potential cause. Most doctors aren't trained to diagnose it." MoldCo patient

What the allergy framework misses

Traditional mold allergy involves the IgE pathway: your body produces antibodies to mold proteins, and subsequent exposure triggers histamine release, sneezing, watery eyes, and sometimes asthma. Allergy tests measure this specific response. If the test is negative, the reasoning goes, mold isn't your problem.

But the innate immune system doesn't work through IgE. It uses pattern-recognition receptors (like TLR4) that detect physical components of fungal cell walls called PAMPs (pathogen-associated molecular patterns). This triggers inflammatory molecules like IL-1beta, TGF-beta1, C4a, and MMP-9. None of these show up on a standard allergy test.

That's why mold allergy and mold illness are different conditions. You can have one without the other. You can have both. A negative allergy test tells you about one pathway. It says nothing about the other.

If you're wondering whether mold could be behind your symptoms, MoldCo's Starter Health Panel measures three biomarkers tied to innate immune activation (MSH, TGF-beta1, and MMP-9) through LabCorp. It's a concrete way to get clarity on whether mold-related illness may be involved.

For a deeper look at the neurological effects, see our article on mold exposure and brain fog.

The measurement problem

Here's something most people don't know: when air quality professionals test for mold using standard spore traps, they're counting intact spores. But mold doesn't only release spores. It sheds tiny fragments of itself constantly.

Cho et al. (2005) measured these fragments and found that for Stachybotrys chartarum, fragments outnumber spores by up to 500 times. Because fragments are smaller, they penetrate 230 times deeper into the respiratory tract. An independent study by Gorny et al. (2002) confirmed similar ratios and verified immunological reactivity using ELISA testing.

A separate 2020 study showed these fragments cause pulmonary inflammation and immune cell infiltration on their own.

So when someone says "your spore counts are low," they may be measuring less than 1% of what you're actually inhaling. Think of it as checking a room's temperature with a broken thermometer and concluding it's comfortable. For more on environmental testing, including what ERMI and HERTSMI-2 scores mean, we've written a separate guide.

The scale of the evidence

The claim that mold causes "only allergies" is sometimes presented as scientific consensus. It isn't.

Dooley and McMahon (2020) reviewed every epidemiological study on mold and human health published between 2011 and 2018. They found 112 of 114 studies (98.2%) supported a link between chronic indoor mold exposure and adverse health effects, whether single-system or multi-system. The review covered 273,000+ subjects across more than 30 countries. Within the subset of papers that ran formal statistical-significance tests, 7 of 16 cognitive studies (44%) and 4 of 10 neurologic studies (40%) reported significant associations.

McMahon's 2017 clinic cohort adds a different kind of evidence. It evaluated 1,061 consecutive patients against existing CIRS case definitions, then compared symptom clusters, lab patterns, and screening tools across age groups (McMahon 2017). That matters because the "only allergies" argument often treats CIRS as if it were built only on vague symptom lists. McMahon's work tested whether symptom clusters and objective lab patterns track together.

The SAIIE protocol matters for the same reason. SAIIE stands for Sequential Activation of Innate Immune Elements. It was designed as a structured re-exposure framework: baseline, treatment response, time away from the building, controlled return to the water-damaged building, repeated symptom and lab tracking, then retreatment (Shoemaker & Maizel 2007). SAIIE is not a consumer self-test and patients should not try to reproduce it on their own. But it directly addresses the question AAAAI says is hard: whether exposure, symptoms, and innate immune markers move together in a time-ordered pattern.

Even within the allergy framework, the numbers are large. A 2015 analysis estimated that 21% of U.S. asthma cases (4.6 million people, $3.5 billion in annual costs) are attributable to dampness and mold, and noted that nonallergic mechanisms play a role.

Clinical data backs this up. Shoemaker and House (2006) documented that mold exposure reliably triggers biomarker abnormalities, treatment reverses both symptoms and biomarkers, and re-exposure produces relapse. In a separate study, they found MSH (a hormonal marker of innate immune function) was abnormally low in 94% of patients with Chronic Inflammatory Response Syndrome (CIRS).

Why do some people get sick and others don't? About 24% of the population carries HLA-DR haplotype variants that prevent proper biotoxin clearance. This figure was first published by Shoemaker, Rash & Simon (2006) in Bioaerosols, Fungi, Bacteria, Mycotoxins and Human Health. In these people, the inflammatory cascade keeps running even after the mold exposure ends (Dooley, Vukelic & Jim 2024). A 2024 systematic review now describes CIRS as a recognized innate immune condition that affects roughly 1 in 4 people.

And the institutional record is clear. The WHO (2009) documented immunological reactions to damp indoor spaces and described perturbation of the immunological system beyond allergic responses. The NIEHS lists cognitive difficulties, anxiety, depression, and immune system changes. The IOM (2004) documented immune effects years before the "only allergies" position statements were even written.

"My life would likely have been quite different the past 8 years had MoldCo been around when I found mold in my house in 2017. It's been a journey even talking publicly about mold illness since it sounds like quackery. Getting help has been even harder. Most doctors downplay the impact of mold." MoldCo patient

Where the "allergy-only" claim came from

The current AAAAI public article is dated 2024, but its argument still rests heavily on the older "mycotoxicosis" frame: if indoor mycotoxin dose is too low to poison people directly, then wide-ranging symptoms shouldn't be attributed to mold. That framing misses the core CIRS claim, which is about chronic innate immune activation in susceptible people, not acute poisoning.

Two older position statements helped shape that frame: the AAAAI 2006 paper and the ACOEM 2002 paper.

A published letter to the Journal of Allergy and Clinical Immunology documented that at least two authors of the AAAAI 2006 paper earned substantial income testifying against patients in mold litigation. The authors didn't disclose this conflict of interest. The letter called the paper "a one-sided opinion paper." The AAAAI 2006 statement is currently archived, meaning it's no longer the society's active position.

A separate peer-reviewed analysis found the ACOEM 2002 position contained undisclosed conflicts of interest and significant methodological problems with its dose-response model. ACOEM discarded their own statement in 2014.

We present this information factually, not as an accusation. Position statements are only as strong as the evidence and objectivity behind them. The scientific community has questioned these particular statements, their own organizations have abandoned them, and two decades of subsequent research has contradicted them.

Evidence standards and limits

We assessed the "allergy-only" claim against controlled experiments (Harding 2020, 2012; Kraft 2021), systematic reviews (Dooley & McMahon 2020, CIRS 2024 review), exposure science (Cho 2005, Gorny 2002, Stachybotrys fragment study 2020), institutional positions from neutral bodies (WHO 2009, IOM 2004, NIEHS), and the source credibility of the position statements themselves (AAAAI 2006 critique, ACOEM 2008 analysis). We didn't rely on case reports or sources outside the peer-reviewed literature for clinical claims. We include patient testimonials to illustrate lived experience, not as evidence for medical claims. For a full list of mold exposure symptoms documented in the literature, we maintain a separate guide.

That said, there are limits to what this evidence can tell you.

The primary mechanistic evidence (Harding 2020) comes from mouse models. The immune pathway exists in humans and the downstream biomarkers are measurable in human patients, but direct human experimental replication of the hippocampal inflammation finding hasn't been published yet. The 98.2% figure from Dooley and McMahon covers epidemiological (observational) studies, which show association, not proof of causation in individual cases. Individual susceptibility varies: about 24% of people carry HLA-DR variants associated with impaired biotoxin clearance, while others may be exposed without developing chronic illness. And environmental factors (airflow, humidity, HVAC systems, duration of water damage) affect exposure levels enormously between buildings.

We don't claim mold causes every illness. We do say the evidence shows the "allergy-only" position is contradicted by controlled experiments, systematic reviews, and institutional findings from the WHO, NIH, and National Academies.

"MoldCo gave me my life back!!! I struggled for years with chronic symptoms that other doctors wanted to give me band-aid solutions for, but with MoldCo, I actually got to the root cause." MoldCo patient

FAQ

If my allergy test for mold is negative, can mold still be making me sick?

Yes. Allergy tests measure IgE-mediated responses. The non-allergic pathway operates independently of IgE. It can cause brain inflammation, memory problems, fatigue, and other multi-system effects. A negative allergy test rules out one pathway. It doesn't rule out the others.

Is there a test that measures innate immune activation from mold?

There are blood biomarkers associated with this pathway, including MMP-9, TGF-beta1, MSH, and C4a. These can be ordered through MoldCo's lab panels via LabCorp. They measure what's happening in your immune system, not whether you're allergic to mold.

Isn't the "mold causes more than allergies" claim fringe science?

No. Nearly all epidemiological studies since 2011 found multi-system effects: 112 of 114 in the most comprehensive review to date. The WHO, the NIH, and the National Academies have all acknowledged health effects beyond allergy. A 2024 systematic review in the Annals of Medicine and Surgery describes CIRS as a recognized innate immune condition. The position statements that call it "only allergies" have been archived or discarded by their own societies.

My doctor says the mold in my home "isn't the toxic kind." Does that matter?

The Harding 2020 experiment directly tested this. Non-toxic spores (with all mycotoxins removed) still caused brain inflammation and memory loss. The non-allergic pathway responds to the physical shell of mold, not its toxicity. So "not the toxic kind" doesn't mean "harmless."

What should I do if I suspect mold is affecting my health?

Start with information, not assumptions. You can get clarity on whether mold-related illness may be involved with blood biomarker testing that measures innate immune markers. MoldCo's Starter Health Panel checks MSH (a hormonal marker), TGF-beta1, and MMP-9, and results come with a clear guide explaining what they mean and what to do next.

What this means

The science has moved. The institutions have moved. The position statements claiming "only allergies" have been archived or discarded. What hasn't caught up is the conversation many patients still have with their doctors and landlords, where a negative allergy test gets treated as the final word.

If you've been told your symptoms can't be from mold because your allergy test was negative, or because the mold in your home "isn't the toxic kind," those reassurances were built on an incomplete picture.

"My experience with MoldCo is genuinely life-changing. I was able to get MoldCo's lab testing early this year after dealing with constant brain fog and feeling like I didn't have the energy to do my work. I was amazed when I received my results because they came with a clear guide that explained what everything meant and what steps I needed to take next." MoldCo patient

The question was never "allergy or toxicity." The question is what's happening in your immune system right now, and whether it explains how you feel.

That's testable. MoldCo's lab testing measures the biomarkers associated with this pathway through LabCorp. If something is off, you'll know. If everything looks normal, you'll know that too. Either way, you stop guessing.

Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. MoldCo assumes no responsibility or liability for any errors or omissions in the content of the references, nor for any actions taken in reliance thereon.